Beijing Sunho Pharmaceutical Co., Ltd

EU EMA（Germany、Poland）

FDA ANDA Pending（expected to be approved on FDA by the end of  2024）

Cafizomide is a proteasome inhibitor that is suitable for the treatment of multiple myeloma in patients who have previously received at least two priority therapies to confirm that the disease is still developing or have completed their most recent treatment within 60 days. Freeze dried powder injection fo...

Carboplatin is a chemotherapy drug used to treat various types of cancer. Including ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma, intravenous injection is used.

Intravenous injection of sodium bicarbonate can directly increase the body's alkaline reserve, quickly correct metabolic acidosis, and alkalize urine to prevent damage to the kidneys caused by metabolites of sulfonamide drugs, accelerate the excretion of weakly acidic drugs, and slow down the excretion of ...

On June 16, 2023, the "2023 Conference on High Quality Development of Healthcare Industry and the 8th Summit for China Pharmaceutical R&D Innovation" was held in Chongqing. This summit has created more high-value communication and cooperation opportunities for pharmaceutical companies to understand the latest cutting-edge developments in pharmaceutical preparations, promote cooperation in drug quality and new formulation development, and create a suitable and competitive R&D pipeline to enhance the market competitiveness of companies.The conference released the list of "Top 20 Chinese CDMO Enterprises in 2023". And Sunho Pharmaceutical was honored to be in the list, which is another high recognition of the industry's professionalism in the field of CDMO services. In the future, Sunho will continue to adhere to the core concept of "Self-surpassing and Co-development" to provide more professional and better services for our customers.